VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ELCC 2017 | Current treatment landscape for neuroendocrine tumors

Keith Kerr • 5 May 2017
ELCC 2017
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the current treatment landscape for neuroendocrine tumors at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. The prognosis for neuroendocrine tumors is not very positive as physicians have been unsuccessful in developing specific targeted therapies. Dr Kerr explains how more investigation is required, especially for treatments that involve biomarker testing.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter